HealtheUniverse Focuses Research To Be First To Commercialize Non-Embryonic Stem Cell Use In The $15 Billion Plastic, Reconstructive, And Cosmetic Surgery Market

Published: Feb 16, 2006

Healtheuniverse Inc. (OTC: HLUN), a diversified biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products, announced today that research efforts are focused on being the first to commercialize non-embryonic stem cell use in the $15 billion worldwide plastic surgery and cosmetic surgery market. The Company intends to sell its proprietary technology through packaged products and licensing agreements, once human clinical trials are completed, to plastic and cosmetic surgeons as a simple way for the industry to utilize our proprietary technology worldwide.

Back to news